OncoSec Medical, Inc. (ONCS)

Oncology Corporate Profile

Stock Performance

1.3000
0.0000

HQ Location

9810 Summers Ridge Road, Suite 110
San Diego, CA 92121

Company Description

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy, and other treatment alternatives.

Website: http://www.oncosec.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ImmunoPulseimmunotherapyMetastatic MelanomaII
ImmunoPulseimmunotherapyTriple negative Breast cancer II
ImmunoPulse (+pembrolizumab)immunotherapyMetastatic MelanomaII

View additional information on product candidates here »

Source


http://www.oncosec.com

Recent News Headlines

OncoSec to Present Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2017

3/28/2017 10:00 am

[PR Newswire] - SAN DIEGO, March 28, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present preclinical ...

OncoSec Medical's Intratumoral Plasmid IL-12 Demonstrates Effectiveness at Enhancing Tumor Immunogenicity in Preclinical Tumor Models

3/21/2017 06:00 pm

[PR Newswire] - SAN DIEGO, March 21, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented a poster ...

OncoSec Announces First Technology Access Program Agreement with Inhibrx

3/14/2017 10:00 am

[PR Newswire] - SAN DIEGO, March 14, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that they ...

OncoSec to Present at Scientific and Investment Conferences in March

3/7/2017 02:02 pm

[PR Newswire] - SAN DIEGO, March 7, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present preclinical ...

OncoSec to Host Second Quarter Financial Conference Call on March 16, 2017

3/2/2017 11:00 am

[PR Newswire] - SAN DIEGO, March 2, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that the ...

OncoSec Granted FDA Fast Track Designation for ImmunoPulse® IL-12 for the Treatment of Metastatic Melanoma Following Progression on Pembrolizumab or Nivolumab

2/27/2017 11:00 am

[PR Newswire] - SAN DIEGO, Feb. 27, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, received Fast Track designation ...

OncoSec to Host KOL Event Focused on New ASCO-SITC Melanoma Data and Clinical Strategy on Tuesday, February 28 in New York City

2/24/2017 11:00 am

[PR Newswire] - SAN DIEGO, Feb. 24, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will host a Key Opinion Leader ...

OncoSec Announces Positive Phase II Data Demonstrating Company's ImmunoPulse® IL-12 in Combination with Pembrolizumab Increased Response Rates in Anti-PD-1 Non-Responder Melanoma Patients

2/23/2017 04:03 pm

[PR Newswire] - SAN DIEGO, Feb. 23, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today reported new positive ...

OncoSec to Present New Clinical Data from Phase 2 Combination Study at ASCO-SITC Clinical Immuno-Oncology Symposium and Corporate Updates at Two Investment Conferences in February

2/8/2017 11:00 am

[PR Newswire] - SAN DIEGO, Feb. 8, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present new clinical ...

OncoSec to Present at NobleCon13

1/26/2017 11:00 am

[PR Newswire] - SAN DIEGO, Jan. 26, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that its ...

OncoSec to Present at Investment Conferences in January

1/3/2017 11:00 am

[PR Newswire] - SAN DIEGO, Jan. 3, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that members ...

LifeSci Capital Initiates Coverage of OncoSec Medical

12/27/2016 07:05 pm

[Accesswire] - Developing DNA-based Oncology Treatments for Patients who do not Respond to Checkpoint Inhibitors; Report Available here: http://www.lifescicapital.com/equity-research/oncosec/ NEW YORK, NY / ACCESSWIRE ...

OncoSec Announces First Quarter Financial Results for Fiscal Year 2017

12/8/2016 09:00 pm

[PR Newswire] - SAN DIEGO, Dec. 8, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced financial ...

OncoSec to Present at the 9th Annual LD Micro Main Event

12/1/2016 11:00 am

[PR Newswire] - SAN DIEGO, Dec. 1, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that Richard ...

OncoSec Announces Key Corporate Initiatives at Inaugural Investor & Analyst Day on November 17, 2016

11/17/2016 11:00 am

[PR Newswire] - SAN DIEGO, Nov. 17, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will provide updates today ...